Print PDF

Sanya Sukduang
+1 202 408 4377

901 New York Avenue, NW
Washington, DC 20001-4413

+1 202 408 4000
Fax +1 202 408 4400

Bar and Court Admissions

  • District of Columbia
  • Maryland
  • U.S. Court of Appeals, Federal Circuit
  • U.S. Patent and Trademark Office


  • American University, Washington College of Law
    J.D., cum laude, 1999
  • Boston College
    B.S., Biology, 1996

Sanya Sukduang


Sanya Sukduang concentrates on patent litigation before federal district courts and the U.S. Court of Appeals for the Federal Circuit, and post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), primarily in the areas of biotechnology, pharmaceuticals, biologics, diagnostics, and medical devices. He has conducted all aspects of pre-trial, trial, post-trial, and inter partes review (IPR) proceedings before the PTAB. Drawing from extensive experience in cases arising from the filing of Abbreviated New Drug Applications (ANDA), Mr. Sukduang advises clients on an array of issues concerning biologics, including due diligence investigations and strategic patent portfolio planning.

Mr. Sukduang lectures in the United States and abroad on biologics and biosimilars arising under the Biologics Price Competition and Innovation Act (BPCIA) and has authored numerous articles on this topic. Since 2013, he has served as an adjunct professor of Hatch-Waxman litigation at the Washington College of Law, having previously served as an adjunct professor of patent law at Howard University Law School, 2007-2012. The former chair of Finnegan's Diversity and Inclusion Committee (2014-2016), Mr. Sukduang is committed to strengthening diversity—both within the firm and throughout the legal profession.


  • Forest Labs v. Apotex (D. Del.). Successfully represented Forest Labs as co-lead counsel in an ANDA litigation for its Savella® (milnacipran) product for the treatment of fibromyalgia against multiple generic drug manufacturers, resulting in a finding of infringement and validity of all asserted claims.
  • Eli Lilly and Co. v. Wockhardt Ltd. (S.D. Ind.). Successfully represented Eli Lilly in an ANDA litigation for its blockbuster drug Cymbalta® against multiple generic drug manufacturers, resulting in orders and judgment maintaining Cymbalta's® market exclusivity through the end of its patent life.
  • Boston Heart v. Health Diagnostic Laboratories (PTAB). Successfully represented HDL as lead counsel in an IPR brought by Boston Heart related to HDL's patent directed to screening methods for pre-diabetes, resulting in PTAB denying instituting the petition.
  • Bonutti v. ConforMIS, Inc. (D. Del.). Lead counsel in obtaining a successful settlement for ConforMIS in a case relating to customizable knee implants.
  • Monsanto v. Syngenta (D. Del., Fed. Cir.). Represented Syngenta Seeds in successfully obtaining summary judgment of non-infringement and invalidity regarding genetically modified corn.
  • Boston Heart v. Health Diagnostic Laboratories (D. Mass.). Lead litigation and ex parte reexamination counsel in defending HDL against patent infringement allegations related to HDL's SLCO1B1 genetic test.
  • Medac Pharma Inc. v. Antares Pharma Inc., (D.N.J., PTAB). Lead litigation and IPR counsel in obtaining a successful settlement for Antares against allegations of infringement concerning Antares' Otrexup® (subcutaneously injectable methotrexate).
  • Forest Labs v. Sigmapharm (D. Del.). Co-lead counsel representing Forest Labs in an ANDA litigation for its Saphris® (asenapine) product for the treatment of schizophrenia and bipolar disorder against multiple generic drug manufacturers.

    Click here for full list of litigation experience highlights.

Professional Recognition

  • Recognized as an "IP Star" in Washington, D.C. by Managing Intellectual Property, 2017.
  • Recognized as a Washington D.C. "Rising Star," 2013; and "Super Lawyer," 2014-2016, in Intellectual Property, Super Lawyers published by Thomson Reuters.
  • Shortlisted for "General Patent Litigator of the Year - DC," at the 2016 and 2017 LMG Life Sciences Awards; and recognized as an "Intellectual Property: Life Sciences Star," LMG Life Sciences, 2012-2016.
  • Recipient of the National Asian Pacific American Bar Association's "Best Lawyers Under 40," 2013.
  • Recipient of Eli Lilly and Company’s "Quality Advocate Award," 2011.

Professional Activities

  • Asian Pacific American Bar Association (chair of partner’s forum, 2008, 2009; newsletter editor, 2007, 2008; secretary, 2006, 2007; vice-president of programs, 2003-2006)
  • Maryland Patent Law Association (president, 2005-present; vice president, 2001-2005)
  • Asian Pacific American Bar Association Education Fund (Board of Directors, 2000-2002)
  • Washington College of Law, Dean’s Diversity Council (Board of Directors, 2002-present)
  • American Intellectual Property Law Association

Select Publications